Self-assembling tissue modules

• US 9,303,245 B2
• Filed: 06/22/2009
• Issued: 04/05/2016
• Est. Priority Date: 06/20/2008
• Status: Active Grant

• Current Assignee: Universiteit Maastricht
• Original Assignee: Universiteit Maastricht
• Inventors: Rivron, Nicolas Clment, Truckenmuller, Roman, Rouwkema, Jeroen, Le Gac, Sverine, Van Blitterswijk, Clemens Antoni, Vrij, Erik Jacob
• Primary Examiner(s): Lankford, Blaine
• Assistant Examiner(s): Visone, Thomas J
• Application Number:
  US12/999,841
• Publication Number:
  US 20110171712A1
• Time in Patent Office: 2,479 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: C12N 2513/00 3D culture
• CPC Class Codes: C12N 2533/52 Fibronectin; Laminin
• CPC Class Codes: C12N 2533/54 Collagen; Gelatin
• CPC Class Codes: C12N 5/0062 General methods for three-dimensional culture
• CPC Class Codes: C12N 5/0663 Bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12N 5/069 Vascular Endothelial cells
• CPC Class Codes: C12N 5/0691 Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels

Abstract

The invention relates to a new approach to constructing cellular aggregates in vitro and their use in methods for producing 3D-tissue constructs in a modular way.

In particular, the invention is directed to a method for in vitro producing a tissue construct comprising:

• a) combining living cells to form supracellular aggregates using spatial confinement;
• b) combining two or more of the supracellular aggregates in a mold or on a biomaterial;
• c) applying conditions that induce self-assembly within the combined supracellular aggregates to obtain the tissue construct; and
• d) applying conditions that induce tissue morphogenesis in the tissue construct.

Claims

1. A method for in vitro producing a tissue construct which substantially retains its shape after release from a well, the method comprising:

a) combining living cells to form supracellular aggregates using spatial confinement by condensation of said cells in microwells having an enveloping diameter in the range of 50 μ

m to 500 μ

m into supracellular aggregates;

b) combining two or more of the supracellular aggregates in a mold or biomaterial comprising a well having a geometric shape and having enveloping diameter of at least 100 μ

m;

c) applying conditions that induce self-assembly within the combined supracellular aggregates to obtain the tissue construct;

d) applying conditions that induce tissue morphogenesis in the tissue construct; and

e) releasing the tissue construct from the well,

wherein the condensation of step a) allows the tissue construct to maintain at least 90% of its non-spherical shape for 150 hours has after said release of the tissue construct from the well having a geometric shape as compared to the shape of the construct while still within the well having geometric shape.

2. The method according to claim 1, wherein said tissue morphogenesis comprises migration and/or differentiation of cells.

3. The method according to claim 1, wherein step (a) further comprises incubating the supracellular aggregates in said microwells having a depth in the range of 100-1,000 μ

m, and adjusting the duration of said incubation, thereby adjusting the plasticity of the formed supracellular aggregates during said self-assembly.

4. The method according to claim 1, wherein the microwells have a shape that is different from a cylinder.

5. The method according to claim 4, wherein the shape of at least some of the microwells is such that the resulting aggregates can self-assemble according to the lock-and-key principle.

6. The method according to claim 1, wherein 2-500,000 cells per microwell are combined to form a supracellular aggregate.

7. The method according to claim 1, wherein the living cells are of the same cell type and are combined to form the supracellular aggregates.

8. The method according to claim 1, wherein the cells are selected from the group consisting of endothelial cells, smooth muscle cells, striated muscle cells, neural cells, connective tissue cells, osteoblasts, osteoclasts, chondrocytes, hepatocytes, cardiomyocytes, myocytes, Schwann cells, urothelial cells, parenchymal cells, epithelial cells, exocrine secretory epithelial cells, epithelial absorptive cells, keratinizing epithelial cells, extracellular matrix secretion cells, or undifferentiated cells, such as embryonic cells, progenitor cells, (mesenchymal) stem cells, bone marrow cells, satellite cells, fibroblasts, and other precursor cells.

9. The method according to claim 1, wherein the supracellular aggregates have a mean particle size of 20-400 μ

m as measured by light microscopy.

10. The method according to claim 1, wherein the biomaterial is selected from the group consisting of ceramics, bioglasses, biodegradable polymeric materials non-biodegradable polymeric materials, and metals.

11. The method according to claim 1, wherein the array of microwells is prepared by microchip technology, hot embossing, selective laser sintering, solid free-form fabrication, or phase separation micromolding.

12. The method according to claim 1, wherein the array of microwells comprises at least two microwells having a substantially different size and/or shape.

13. The method according to claim 1, wherein the microwells are made of agarose, PEG (polyethyleneglycol) or PDMS.

14. The method according to claim 1, wherein the microwell surface is coated with one or more compounds capable of reducing and/or preventing cellular adhesion, selected from the group consisting of polyethylene glycol and bovine serum albumin.

15. The method according to claim 1, wherein the living cells are combined in the presence of fibronectin and/or collagen.

16. The method according to claim 1, wherein the surface properties, the magnetic charge, and/or the electrical charge of the supracellular aggregates are modified before combining two or more of the supracellular aggregates.

17. The method according to claim 1, wherein the supracellular aggregates are combined in a in a microfluidic chamber and/or microfluidic channel.

18. The method according to claim 1, wherein the conditions in step c) comprise one or more selected from mechanical constraints, compression, shaking, electrical fields, magnetic fields, and gradients of morphogens or growth factors.

19. The method according to claim 1, wherein in step a) or b) the living cells or the supracellular aggregate is combined with an object and/or wherein in step c) or d) the tissue construct is combined with a metallic material and/or a polymeric material, to induce a local response.

20. The method according to claim 1, wherein the method further comprises remodeling the tissue construct into a desired geometry by utilizing a well having a geometry that compensates for relatively greater compaction in the corners of the well.

21. The method according to claim 1, wherein the method further comprises a step of assembling the non-spherical tissue construct in centimeter scale tissues.

22. The method according to claim 1, wherein in step (d) the tissue morphogenesis-inducing conditions include local deformation, compaction of the tissue construct and subsequent local biological changes resulting in spatial heterogeneity by applying geometrical constraints to the tissue construct.

23. The method according to claim 1, wherein in step (d) the conditions that induce tissue morphogenesis include self-deformation of the tissue construct.

24. The method according to claim 1, wherein the well having a geometric shape in step (b) is a cylinder or blocks in the form of cubes or triangles and wherein self-assembly of the aggregates in step (c) is into the cylinder or blocks in the form of cubes or triangles such that when releasing the tissue construct from the well, the tissue construct have the non-spherical shape of the cylinder or the blocks in the form of cubes or triangles.

25. The method according to claim 7, wherein a first type of supracellular aggregates of a first cell type is combined with a second type of supracellular aggregates of a second cell type, and wherein said first and second cell type are different from each other.

26. The method according to claim 25, wherein the first cell type is HUVEC (Human Umbilical Vein Endothelial Cells) and the second cell type is hMSC (human Mesenchymal Stem Cells), and combining at least 5000 supracellular aggregates of HUVEC and at least 5000 supracellular aggregates of hMSC in a single well in the shape of a trench in step b), to form a cylindrical tissue construct comprising a primitive capillary network formation.

27. The method according to claim 1, wherein the microwell array is formed of a PDMS (polydimethyelsiloxane) composition comprising from 10:

0.5 to 10;

1 mass ratio of base to current agent, coated with a coating of more than 10 mg/ml of BSA (Bovine Serum Albumin) or a coating of more than 10 mg/ml of 35,000 molecular weight PEG.